BPC-157 and TB-500 get grouped together constantly. They show up in the same catalog category, they are sold as a combined blend, and most of what gets written about them treats the pair as interchangeable. They are not interchangeable. They come from different source proteins, they act through different pathways, and the published literature on each one examines different tissue models.
This guide covers what each compound is, how the two differ at the mechanism level, why they are studied in combination, and what the specification differences look like when you are ordering either one. Both compounds are supplied for laboratory and research use only. Nothing here is guidance on administration, and no dosing values appear anywhere in this post.
What BPC-157 is
BPC-157 is a synthetic pentadecapeptide - fifteen amino acids, sequence GEPPPGKPADDAGLV. Its originators describe it as a partial sequence of a larger protein they designated Body Protection Compound, identified in human gastric juice - a parent protein whose full sequence has never been independently published or confirmed, which honest coverage should note. The research program around it dates to the early 1990s and is closely associated with Sikiric and colleagues at the University of Zagreb, whose group produced the bulk of the early rodent literature.
The structural detail that gets cited most often is stability. Published characterization work reports that BPC-157 remains intact in human gastric juice for extended periods, which is unusual for a peptide of that length and is the reason so much of the early literature centers on gastrointestinal models.
Mechanistically, BPC-157 is studied as a signaling modulator rather than a receptor agonist with one clean binding target. The pathways that recur across the literature are VEGFR2 activation and downstream nitric oxide signaling, the FAK-paxillin cascade associated with cell migration, and upregulation of growth hormone receptor expression in tendon fibroblast cultures. Several rodent papers also examine interactions with dopaminergic and serotonergic systems, which is why BPC-157 shows up in central nervous system literature that has nothing to do with tissue repair.
WWP lists it as BPC-157 in 5mg and 10mg vial sizes.
What TB-500 is
TB-500 is a synthetic acetylated fragment corresponding to residues 17-23 of thymosin beta-4, sequence LKKTETQ. Thymosin beta-4 itself is a 43-amino-acid polypeptide first isolated from bovine thymus in 1981 by Low and Goldstein. It is the principal G-actin-sequestering peptide in mammalian cells, present at high intracellular concentrations, and its primary characterized function is holding G-actin, the monomeric form of the cytoskeletal protein actin, in reserve.
The seven-residue fragment is the conserved actin-binding motif - the major contact site, though full actin sequestration in the parent molecule also involves an N-terminal helix the fragment lacks. The fragment is the shorter, cheaper, more stable molecule to make, which is why the market settled on it - though published analytical work has found at least some material sold under the TB-500 label to contain the full-length polypeptide instead, one more reason batch documents matter.
This creates a naming problem worth being precise about. “TB-500” and “thymosin beta-4” are used as synonyms in commercial listings, but they are not the same molecule. TB-500 is a fragment. Full-length thymosin beta-4 is the parent protein. Papers that study Tβ4 in cardiac or corneal models are usually studying the full protein, not the fragment, and that distinction matters when reading the literature.
WWP lists this compound as TB-4 (Thymosin Beta-4) in 5mg and 10mg vial sizes.
Mechanism comparison
| Pathway or property | BPC-157 | TB-500 (thymosin beta-4 fragment) | What the difference means in studies |
|---|---|---|---|
| Parent molecule | Partial sequence of Body Protection Compound, from gastric juice | Fragment of thymosin beta-4, an intracellular actin-binding protein | Different biological origin entirely, not variants of one another |
| Length | 15 amino acids | 7 amino acids (acetylated) | TB-500 is the smaller and simpler of the two |
| Primary characterized action | Signaling modulation across several pathways, no single confirmed receptor | G-actin sequestration, direct cytoskeletal interaction | BPC-157 literature is pathway-level; TB-500 literature is structural |
| Angiogenesis route | VEGFR2 activation with downstream nitric oxide signaling | Endothelial cell migration driven by actin remodeling | Both are examined in vascular models but arrive there differently |
| Cell migration | FAK-paxillin pathway activation reported in fibroblast studies | Actin monomer availability governing cytoskeletal assembly | Both feed migration assays, through separate machinery |
| Inflammatory signaling | Modulation reported in gut and systemic rodent models | Downregulation of inflammatory cytokines reported in Tβ4 literature | Overlapping study endpoints, different upstream steps |
| Most-studied tissue models | Gastrointestinal tract, tendon and ligament, central nervous system | Cardiac tissue, cornea, dermal wound models | The literature bodies barely overlap |
| Reported stability | Stable in gastric juice per published characterization | Standard short-peptide profile | Explains why oral-route papers exist for one and not the other |
Where the two actually diverge
The simplest way to hold the difference: BPC-157 research is mostly about signaling, and TB-500 research is mostly about structure.
BPC-157 papers tend to measure what happens downstream of a pathway being switched on. Vessel formation, gene expression changes such as egr-1 and NAB2, receptor upregulation, neurotransmitter system interactions. There is no confirmed single receptor for BPC-157, which is a real gap in the literature and something honest coverage should say plainly.
TB-500 papers tend to measure what happens when actin monomer availability changes. Cell migration rates, cytoskeletal assembly, endothelial motility. The mechanism is better defined at the molecular level, and the ambiguity sits elsewhere: it is not fully established how much of the full protein’s reported activity carries over to the seven-residue fragment sold commercially.
Those are different kinds of uncertainty. One compound has a well-characterized binding interaction and a question about whether the fragment behaves like the parent. The other has a large body of downstream observations and a question about what it binds to in the first place.
Why the two are studied together
The combined pack exists because researchers designing repair-model studies frequently want both a signaling arm and a cytoskeletal arm in the same protocol. If BPC-157 is examined for pathway-level effects on vessel formation and TB-500 is examined for cell migration behavior, a combination arm lets a study look at whether the two produce additive, redundant, or interfering results on shared endpoints.
That is the honest version. The less honest version, which appears across most of the search results for this pair, is that the two are “synergistic.” Published head-to-head comparison data on the combination is thin. Combination arms appear in a small number of papers, and most of the material asserting synergy online is repeating a claim rather than citing a result. If you are designing around this pair, treat the combination as an open question your own work is testing, not a settled finding.
The practical reason the blend is stocked as a single item is more mundane: two compounds in one vial is one preparation step instead of two and one line item instead of two. WWP supplies it as BPC-157 / TB-500 in 5/5mg and 10/10mg configurations.
The same logic extends further up the stack. Multi-component blends such as GLOW add GHK-Cu to the same two compounds, and KLOW adds KPV on top of that. We break down what separates those two in KLOW vs GLOW.
Research applications examined for each
Neither list below is a claim about outcomes. These are the study categories the published literature falls into.
BPC-157 appears in research examining:
- Gastrointestinal mucosal models, including the gastric and intestinal lesion work that anchors the early literature
- Tendon and ligament fibroblast cultures, with attention to growth hormone receptor expression
- Angiogenesis assays measuring VEGFR2 and nitric oxide pathway involvement
- Central nervous system models covering dopaminergic and serotonergic system interactions
- Nitric oxide system interaction studies, including work using NO synthase blockers
- Gene expression profiling, particularly egr-1 and NAB2
TB-500 and thymosin beta-4 appear in research examining:
- Actin sequestration and cytoskeletal assembly at the molecular level
- Cell migration and endothelial motility assays
- Cardiac tissue models, following the 2004 Nature work on Tβ4 in myocardial repair
- Corneal and dermal wound-model literature
- Inflammatory cytokine expression profiling
- Laminin-5 expression and related extracellular matrix work
Note that most of the cardiac and corneal literature uses full-length thymosin beta-4, not the LKKTETQ fragment. Anyone citing that work in a study designed around TB-500 should say which molecule the source paper used.
Specification differences
| BPC-157 | TB-4 (Thymosin Beta-4) | BPC-157 / TB-500 blend | |
|---|---|---|---|
| Format | Lyophilized powder | Lyophilized powder | Lyophilized powder |
| Purity | ≥99% | ≥99% | ≥99% |
| Vial sizes offered | 5mg, 10mg | 5mg, 10mg | 5/5mg, 10/10mg |
| Pack size | 10 vials | 10 vials | 10 vials |
| Aliases | Body Protection Compound 157, PL 14736, pentadecapeptide BPC-157 | TB-500, Tβ4 fragment, LKKTETQ | Often listed by vendors as a combined repair blend |
| Storage | 2-8°C unopened, stable 12+ months | 2-8°C unopened, stable 12+ months | 2-8°C unopened, stable 12+ months |
| Use | Research purposes only, not for human use | Research purposes only, not for human use | Research purposes only, not for human use |
Two practical notes. First, the vial sizes are not equivalent in cost terms across compounds - TB-500 carries a higher per-milligram price than BPC-157, which is why the blend prices between the two single compounds at the same nominal total milligram count. Second, every WWP product is a 10-vial pack. There are no single-vial listings.
Regulatory status, stated plainly
Both compounds are unapproved substances. Neither is approved by the FDA for human use in any form. Both spent 2023 to early 2026 on the FDA’s Category 2 compounding list of bulk substances flagged for significant safety risks, and both were removed from that category in April 2026 and referred for advisory committee review - a status change, not an approval.
On the anti-doping side, thymosin beta-4 and its fragments fall under the WADA prohibited list in the growth factors category, prohibited at all times. BPC-157 is prohibited under the non-approved substances category. USADA has published a specific advisory on BPC-157 for athletes.
We state this because it is true and because anyone doing serious work with either compound needs to know it. Research supply and human use are different categories, and this distinction is the whole basis on which these compounds are sold.
Common questions about BPC-157 and TB-500 research
What is the difference between BPC-157 and TB-500?
They are unrelated molecules with different origins. BPC-157 is a fifteen-amino-acid sequence derived from a protein found in gastric juice, and the literature on it centers on signaling pathways including VEGFR2 and nitric oxide. TB-500 is a seven-amino-acid fragment of thymosin beta-4, an actin-binding protein, and the literature on it centers on cytoskeletal behavior and cell migration. They are studied in some of the same model systems, which is why they get grouped, but they are not variants of one compound.
Is TB-500 the same thing as thymosin beta-4?
Not exactly. Thymosin beta-4 is a 43-amino-acid polypeptide. TB-500 is a synthetic acetylated fragment corresponding to residues 17-23, the actin-binding region. Commercial listings use the two names interchangeably, but published papers on the full protein and papers on the fragment are studying different molecules, and the results from one do not automatically apply to the other.
Why do research catalogs sell BPC-157 and TB-500 as a combined blend?
Because study designs that examine tissue-repair endpoints often want both a signaling-pathway arm and a cytoskeletal arm running against the same model. Supplying them pre-combined removes a preparation step. The blend format is a logistical convenience, not evidence that the combination has been validated as superior to either compound alone. Head-to-head combination data in the published literature is limited.
Which one has more published research behind it?
Thymosin beta-4 has substantially more total published papers, with a broad institutional base and more work in larger animal models, particularly cardiac. The BPC-157 literature is smaller and concentrated heavily in rodent models from a small number of research groups. Neither has completed the kind of large human trial program that would settle the open questions in either literature.
Are BPC-157 and TB-500 approved for human use?
No. Both are unapproved substances sold for laboratory and research use only, not for human consumption, ingestion, injection, or therapeutic use. Both are also prohibited under anti-doping rules for competing athletes. Any published values relating to administration exist in the research literature and are not guidance from us.
How do you confirm what is actually in the vial?
By testing it. Purity claims from any vendor, including ours, are claims until an independent lab confirms them. Our COA library publishes third-party test results by product and batch. Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.
What to order for a comparison study
If the goal is a clean comparison between the two compounds, order them separately rather than as the blend. A blend arm cannot tell you which component produced which result. The standard structure is a BPC-157 arm, a TB-500 arm, a combination arm, and a control, which is four lines rather than one.
If the goal is a combination protocol you already have a rationale for, the combined pack is the simpler line item.
WWP ships in 10-vial packs, manufacturer-direct, with a 5-pack minimum per order across either shipping line. Both compounds are stocked in both vial sizes.
- BPC-157 - 5mg and 10mg
- TB-4 (Thymosin Beta-4) - 5mg and 10mg
- BPC-157 / TB-500 blend - 5/5mg and 10/10mg
- GLOW blend - adds GHK-Cu to the same two compounds
All products sold by World Wide Peptides are for laboratory and research use only. They are not for human consumption, ingestion, injection, or therapeutic use, and we do not provide protocol design, dosing guidance, or administration parameters.